Finding 1057234 (2020-006)

Significant Deficiency Repeat Finding
Requirement
M
Questioned Costs
-
Year
2020
Accepted
2024-08-09

AI Summary

  • Core Issue: AAPT did not document pre-award risk assessments for subrecipients, violating 2 CFR 200.331 requirements.
  • Impacted Requirements: Lack of risk evaluation may lead to oversight gaps, allowing higher-risk subrecipients to operate without proper monitoring.
  • Recommended Follow-Up: AAPT should adhere to internal policies, document risk assessments, and establish a clear monitoring framework based on risk levels.

Finding Text

Finding 2020-006: Subrecipient Monitoring Federal Programs: Research and Development Cluster: 47.076 - STEM +C Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation): As stated in 2 CFR 200.331 part (b), all pass-through entities must evaluate each subrecipient's risk of noncompliance with Federal statutes, regulations, and the terms and conditions of the subaward for purposes of determining the appropriate subrecipient monitoring procedures to prescribe to each individual subrecipient. Condition: During our audit work over subrecipient monitoring, we were unable to verify that pre-award risk assessment procedures were performed. It is our understanding that AAPT has ongoing relationships with these subrecipients and evaluation of these subrecipients' risk is a continual process; however, these procedures were not documented. Cause: AAPT’s internal policies and procedures governing risk assessment on subrecipient was not performed. Effect or Potential Effect: AAPT could inadvertently engage in relationships with subrecipients of higher risk without the appropriate level of oversight to ensure subrecipients are expending funds in accordance with the provisions and terms of the subaward. Questioned Costs: None noted. Context: Our audit procedures consisted of examining documentation of the subrecipient monitoring process, and evaluating internal controls over the process. Identification as a Repeat Finding, if Applicable: 2019-005. Recommendation: We recommend AAPT follow their internal policies and procedures surrounding subrecipients and document the risk assessment criteria for the purpose of determining the expected level of oversight during the period of performance. This evaluation should include a scaling system, such as high, medium or low risk (for example), and the monitoring tools and procedures to be performed at each of these levels (additional training, on-site reviews, types of and frequency of reporting, etc.). Views of Responsible Officials and Planned Corrective Actions: Management will continue to perform risk assessment procedures and will thoroughly document the processes and evaluations. Anticipated Completion Date: 12/17/2021 Responsible Official: Michael Brosnan, CFO

Categories

Subrecipient Monitoring Period of Performance

Other Findings in this Audit

  • 480780 2020-003
    Material Weakness Repeat
  • 480781 2020-005
    Significant Deficiency Repeat
  • 480782 2020-003
    Material Weakness Repeat
  • 480783 2020-005
    Significant Deficiency Repeat
  • 480784 2020-003
    Material Weakness Repeat
  • 480785 2020-004
    Significant Deficiency
  • 480786 2020-005
    Significant Deficiency Repeat
  • 480787 2020-003
    Material Weakness Repeat
  • 480788 2020-004
    Significant Deficiency
  • 480789 2020-005
    Significant Deficiency Repeat
  • 480790 2020-003
    Material Weakness Repeat
  • 480791 2020-005
    Significant Deficiency Repeat
  • 480792 2020-006
    Significant Deficiency Repeat
  • 480793 2020-003
    Material Weakness Repeat
  • 480794 2020-005
    Significant Deficiency Repeat
  • 480795 2020-003
    Material Weakness Repeat
  • 480796 2020-004
    Significant Deficiency
  • 480797 2020-005
    Significant Deficiency Repeat
  • 480798 2020-003
    Material Weakness Repeat
  • 480799 2020-005
    Significant Deficiency Repeat
  • 480800 2020-003
    Material Weakness Repeat
  • 480801 2020-005
    Significant Deficiency Repeat
  • 480802 2020-003
    Material Weakness Repeat
  • 480803 2020-005
    Significant Deficiency Repeat
  • 480804 2020-003
    Material Weakness Repeat
  • 480805 2020-005
    Significant Deficiency Repeat
  • 480806 2020-003
    Material Weakness Repeat
  • 480807 2020-005
    Significant Deficiency Repeat
  • 480808 2020-003
    Material Weakness Repeat
  • 480809 2020-005
    Significant Deficiency Repeat
  • 480810 2020-003
    Material Weakness Repeat
  • 480811 2020-005
    Significant Deficiency Repeat
  • 480812 2020-003
    Material Weakness Repeat
  • 480813 2020-005
    Significant Deficiency Repeat
  • 480814 2020-005
    Significant Deficiency Repeat
  • 480815 2020-005
    Significant Deficiency Repeat
  • 480816 2020-005
    Significant Deficiency Repeat
  • 1057222 2020-003
    Material Weakness Repeat
  • 1057223 2020-005
    Significant Deficiency Repeat
  • 1057224 2020-003
    Material Weakness Repeat
  • 1057225 2020-005
    Significant Deficiency Repeat
  • 1057226 2020-003
    Material Weakness Repeat
  • 1057227 2020-004
    Significant Deficiency
  • 1057228 2020-005
    Significant Deficiency Repeat
  • 1057229 2020-003
    Material Weakness Repeat
  • 1057230 2020-004
    Significant Deficiency
  • 1057231 2020-005
    Significant Deficiency Repeat
  • 1057232 2020-003
    Material Weakness Repeat
  • 1057233 2020-005
    Significant Deficiency Repeat
  • 1057235 2020-003
    Material Weakness Repeat
  • 1057236 2020-005
    Significant Deficiency Repeat
  • 1057237 2020-003
    Material Weakness Repeat
  • 1057238 2020-004
    Significant Deficiency
  • 1057239 2020-005
    Significant Deficiency Repeat
  • 1057240 2020-003
    Material Weakness Repeat
  • 1057241 2020-005
    Significant Deficiency Repeat
  • 1057242 2020-003
    Material Weakness Repeat
  • 1057243 2020-005
    Significant Deficiency Repeat
  • 1057244 2020-003
    Material Weakness Repeat
  • 1057245 2020-005
    Significant Deficiency Repeat
  • 1057246 2020-003
    Material Weakness Repeat
  • 1057247 2020-005
    Significant Deficiency Repeat
  • 1057248 2020-003
    Material Weakness Repeat
  • 1057249 2020-005
    Significant Deficiency Repeat
  • 1057250 2020-003
    Material Weakness Repeat
  • 1057251 2020-005
    Significant Deficiency Repeat
  • 1057252 2020-003
    Material Weakness Repeat
  • 1057253 2020-005
    Significant Deficiency Repeat
  • 1057254 2020-003
    Material Weakness Repeat
  • 1057255 2020-005
    Significant Deficiency Repeat
  • 1057256 2020-005
    Significant Deficiency Repeat
  • 1057257 2020-005
    Significant Deficiency Repeat
  • 1057258 2020-005
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
47.049 Mathematical and Physical Sciences $10,562
47.076 Education and Human Resources $6,442
43.001 Science $4,172